Holen Sie sich die Stockscreener-App
12.10
0.62%
0.085
Schlusskurs vom Vortag:
$12.01
Offen:
$12.5
24-Stunden-Volumen:
123.48K
Relative Volume:
0.56
Marktkapitalisierung:
$187.91M
Einnahmen:
$26,600
Nettoeinkommen (Verlust:
$-14.73M
KGV:
-1.7732
EPS:
-6.8211
Netto-Cashflow:
$-8.76M
1W Leistung:
-4.16%
1M Leistung:
-12.96%
6M Leistung:
+47.02%
1J Leistung:
+50.12%
1-Tages-Spanne:
$12.03
$12.75
1-Wochen-Bereich:
$11.77
$12.99
52-Wochen-Spanne:
$4.86
$17.40
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Firmenname
Kazia Therapeutics Limited Adr
Sektor
Branche
Telefon
01161298780088
Adresse
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Compare KZIA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
12.09 | 186.74M | 26,600 | -14.73M | -8.76M | -6.8211 |
VRTX
Vertex Pharmaceuticals Inc
|
521.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.21 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.49 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.88 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Laidlaw | Buy |
| 2025-02-06 | Eingeleitet | Maxim Group | Buy |
| 2021-10-14 | Eingeleitet | Maxim Group | Buy |
| 2021-01-05 | Eingeleitet | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr Aktie (KZIA) Neueste Nachrichten
Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research
Paxalisib shrinks tumors in models as Kazia (NASDAQ: KZIA) lines up Phase 2 cancer trials - Stock Titan
BTIG raises Kazia Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Kazia Therapeutics Expands Trial in HR+/HER2- Cancer | KZIA Stock News - Stock Titan
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering - The Manila Times
Kazia Therapeutics (NASDAQ: KZIA) unveils new investor site - Stock Titan
Kazia Therapeutics LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Kazia Therapeutics stock falls on $40M public offering By Investing.com - Investing.com UK
Kazia Therapeutics prices $40 million public offering By Investing.com - Investing.com UK
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering - The Globe and Mail
Kazia Therapeutics (KZIA) trims at-the-market offering program to $80M - Stock Titan
Kazia Therapeutics Limited Announces Proposed Public Offering - BioSpace
Jorey Chernett (NASDAQ: KZIA) reports multi-million ADS stake - Stock Titan
Ikarian Capital (KZIA) discloses 575,778 Kazia Therapeutics ADSs under 4.9% cap - Stock Titan
Kazia Therapeutics (KZIA) investor group reports 4.6% beneficial stake via ADS - Stock Titan
Kazia Therapeutics (KZIA) Holds Near $13.95 as Biotech ADR Consolidates Between Key LevelsParabolic SAR - Vinanet
Kazia files patent for breast cancer treatment strategy By Investing.com - Investing.com Nigeria
Kazia Therapeutics (NASDAQ: KZIA) files patent backed by TNBC data - Stock Titan
KZIA|Kazia Therapeutics Ltd|Price:12.802|Chg%:+0.542 - TradingKey
Kazia Therapeutics (KZIA) grants director 100,000 stock options - Stock Titan
KAZIA (NASDAQ: KZIA) CEO receives 150K RSUs and 500K stock options grant - Stock Titan
Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance - Stock Titan
Kazia Therapeutics (KZIA) director awarded 100,000 ADS stock options - Stock Titan
Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director - Stock Titan
Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78 - Stock Titan
BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com - Investing.com Nigeria
BTIG initiates Kazia Therapeutics stock with buy on cancer drug - Investing.com
Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA) - TradingView
Kazia Therapeutics (KZIA) awards 250,000 stock options to CSO - Stock Titan
ETFs Investing in Kazia Therapeutics Ltd Sponsored ADR Stocks - TradingView
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Kazia Therapeutics (KZIA) Surges 13.88% as Biotech Momentum AcceleratesHot Stock Picks - DonanımHaber
KZIA News | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) director details existing ADS option grants - Stock Titan
Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth - The Globe and Mail
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 232,956 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 95,110 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO - Stock Titan
KZIAKazia Therapeutics Limited ADR Options - Finviz
Kazia Therapeutics (NASDAQ: KZIA) holder reports 18.5% stake in ADS - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Phase 1b trial, enrollment to 36 patients - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Paxalisib Phase 1b, files prospectus - Stock Titan
Kazia (NASDAQ: KZIA) expands Phase 1b, registers 266,666 ADSs - Stock Titan
Paxalisib breast cancer trial triples size at Kazia (NASDAQ: KZIA) - Stock Titan
Kazia expands paxalisib trial enrollment to 36 patients in TNBC - Investing.com
KZIA Stock Price, Quote & Chart | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) Chief Scientific Officer Sudha Rao files initial Form 3 - Stock Titan
KZIA | Kazia Therapeutics Limited American Insider Trading - Quiver Quantitative
KZIA SEC FilingsKazia Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
Finanzdaten der Kazia Therapeutics Limited Adr-Aktie (KZIA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):